The Europe Rare Diseases Treatment Market would witness market growth of 12% CAGR during the forecast period (2022-2028).
Manufacturers of the new drugs benefit from tax breaks, quick approvals, and other research grants, allowing for much more innovation. Product development can lead to technological products and medical or pharmaceutical innovations that can be utilized to expand into new markets. The general public is conscious of such rare diseases, and this awareness is growing as a result of the government's efforts.
Adding to this scenario, cost recovery strategies in developed nations are driving up the demand for rare disease treatments. Ignorance of rare diseases can be more expensive than research aimed at increasing knowledge. Rare genetic diseases frequently affect patients at a young age and reduce life expectancy, so affected individuals may need health care for the rest of their lives.
The adoption of more advanced home healthcare equipment, as well as the launch of innovative value-based payment and service models, have created a profitable investment opportunity in U.K. healthcare. As the region's healthcare industry expands, the regional market players are contributing heavily in the development of advanced rare diseases treatment in the region. With R&D corporation tax relief, the UK encourages investment as well as rewards innovation in the healthcare life sciences & technology sector. As a result of this, vendors are increasingly investing in the Europe region.
The Germany market dominated the Europe Rare Diseases Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16,772 million by 2028. The UK market would experience a CAGR of 11.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 12.9% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Rare Diseases Treatment Market will Hit $255.4 Billion by 2028, at a CAGR of 12.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Biologics
- Biosimilar
- Small Molecule
By Distribution Channel
- Specialty Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Route of Administration
By Therapeutic Area
- Cancer
- Cardiovascular Conditions
- Infectious Diseases
- Musculoskeletal Conditions
- Endocrine Disorders
- Metabolic Disorders
- Hematologic Disorders
- Neurological Conditions
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- AbbVie, Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Merck Group
- Bristol Myers Squibb Company
- Pfizer, Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- PTC Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Rare Diseases Treatment Market, by Drug Type
1.4.2 Europe Rare Diseases Treatment Market, by Distribution Channel
1.4.3 Europe Rare Diseases Treatment Market, by Route of Administration
1.4.4 Europe Rare Diseases Treatment Market, by Therapeutic Area
1.4.5 Europe Rare Diseases Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
Chapter 4. Europe Rare Diseases Treatment Market by Drug Type
4.1 Europe Biologics Market by Country
4.2 Europe Biosimilar Market by Country
4.3 Europe Small Molecule Market by Country
Chapter 5. Europe Rare Diseases Treatment Market by Distribution Channel
5.1 Europe Specialty Pharmacy Market by Country
5.2 Europe Hospital Pharmacy Market by Country
5.3 Europe Online Pharmacy Market by Country
Chapter 6. Europe Rare Diseases Treatment Market by Route of Administration
6.1 Europe Injectable Market by Country
6.2 Europe Oral Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Rare Diseases Treatment Market by Therapeutic Area
7.1 Europe Cancer Market by Country
7.2 Europe Cardiovascular Conditions Market by Country
7.3 Europe Infectious Diseases Market by Country
7.4 Europe Musculoskeletal Conditions Market by Country
7.5 Europe Endocrine Disorders Market by Country
7.6 Europe Metabolic Disorders Market by Country
7.7 Europe Hematologic Disorders Market by Country
7.8 Europe Neurological Conditions Market by Country
7.9 Europe Others Market by Country
Chapter 8. Europe Rare Diseases Treatment Market by Country
8.1 Germany Rare Diseases Treatment Market
8.1.1 Germany Rare Diseases Treatment Market by Drug Type
8.1.2 Germany Rare Diseases Treatment Market by Distribution Channel
8.1.3 Germany Rare Diseases Treatment Market by Route of Administration
8.1.4 Germany Rare Diseases Treatment Market by Therapeutic Area
8.2 UK Rare Diseases Treatment Market
8.2.1 UK Rare Diseases Treatment Market by Drug Type
8.2.2 UK Rare Diseases Treatment Market by Distribution Channel
8.2.3 UK Rare Diseases Treatment Market by Route of Administration
8.2.4 UK Rare Diseases Treatment Market by Therapeutic Area
8.3 France Rare Diseases Treatment Market
8.3.1 France Rare Diseases Treatment Market by Drug Type
8.3.2 France Rare Diseases Treatment Market by Distribution Channel
8.3.3 France Rare Diseases Treatment Market by Route of Administration
8.3.4 France Rare Diseases Treatment Market by Therapeutic Area
8.4 Russia Rare Diseases Treatment Market
8.4.1 Russia Rare Diseases Treatment Market by Drug Type
8.4.2 Russia Rare Diseases Treatment Market by Distribution Channel
8.4.3 Russia Rare Diseases Treatment Market by Route of Administration
8.4.4 Russia Rare Diseases Treatment Market by Therapeutic Area
8.5 Spain Rare Diseases Treatment Market
8.5.1 Spain Rare Diseases Treatment Market by Drug Type
8.5.2 Spain Rare Diseases Treatment Market by Distribution Channel
8.5.3 Spain Rare Diseases Treatment Market by Route of Administration
8.5.4 Spain Rare Diseases Treatment Market by Therapeutic Area
8.6 Italy Rare Diseases Treatment Market
8.6.1 Italy Rare Diseases Treatment Market by Drug Type
8.6.2 Italy Rare Diseases Treatment Market by Distribution Channel
8.6.3 Italy Rare Diseases Treatment Market by Route of Administration
8.6.4 Italy Rare Diseases Treatment Market by Therapeutic Area
8.7 Rest of Europe Rare Diseases Treatment Market
8.7.1 Rest of Europe Rare Diseases Treatment Market by Drug Type
8.7.2 Rest of Europe Rare Diseases Treatment Market by Distribution Channel
8.7.3 Rest of Europe Rare Diseases Treatment Market by Route of Administration
8.7.4 Rest of Europe Rare Diseases Treatment Market by Therapeutic Area
Chapter 9. Company Profiles
9.1 AbbVie, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Acquisition and Mergers:
9.3 Bayer AG
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Approval and Trails:
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.6 Bristol Myers Squibb Company
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Acquisition and Mergers:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional & Segmental Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Acquisitions and Mergers:
9.8 AstraZeneca PLC
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisition and Mergers:
9.8.5.2 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisition and Mergers:
9.10. PTC Therapeutics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Acquisition and Mergers:
TABLE 1 Europe Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 2 Europe Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements – Rare Disease Treatment Market
TABLE 4 Acquisition and Mergers – Rare Disease Treatment Market
TABLE 5 Approvals and Trials – Rare Disease Treatment Market
TABLE 6 Europe Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 7 Europe Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 8 Europe Biologics Market by Country, 2018 - 2021, USD Million
TABLE 9 Europe Biologics Market by Country, 2022 - 2028, USD Million
TABLE 10 Europe Biosimilar Market by Country, 2018 - 2021, USD Million
TABLE 11 Europe Biosimilar Market by Country, 2022 - 2028, USD Million
TABLE 12 Europe Small Molecule Market by Country, 2018 - 2021, USD Million
TABLE 13 Europe Small Molecule Market by Country, 2022 - 2028, USD Million
TABLE 14 Europe Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 15 Europe Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 16 Europe Specialty Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 17 Europe Specialty Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 18 Europe Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 19 Europe Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 20 Europe Online Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 21 Europe Online Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 22 Europe Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 23 Europe Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 24 Europe Injectable Market by Country, 2018 - 2021, USD Million
TABLE 25 Europe Injectable Market by Country, 2022 - 2028, USD Million
TABLE 26 Europe Oral Market by Country, 2018 - 2021, USD Million
TABLE 27 Europe Oral Market by Country, 2022 - 2028, USD Million
TABLE 28 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 29 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 30 Europe Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 31 Europe Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 32 Europe Cancer Market by Country, 2018 - 2021, USD Million
TABLE 33 Europe Cancer Market by Country, 2022 - 2028, USD Million
TABLE 34 Europe Cardiovascular Conditions Market by Country, 2018 - 2021, USD Million
TABLE 35 Europe Cardiovascular Conditions Market by Country, 2022 - 2028, USD Million
TABLE 36 Europe Infectious Diseases Market by Country, 2018 - 2021, USD Million
TABLE 37 Europe Infectious Diseases Market by Country, 2022 - 2028, USD Million
TABLE 38 Europe Musculoskeletal Conditions Market by Country, 2018 - 2021, USD Million
TABLE 39 Europe Musculoskeletal Conditions Market by Country, 2022 - 2028, USD Million
TABLE 40 Europe Endocrine Disorders Market by Country, 2018 - 2021, USD Million
TABLE 41 Europe Endocrine Disorders Market by Country, 2022 - 2028, USD Million
TABLE 42 Europe Metabolic Disorders Market by Country, 2018 - 2021, USD Million
TABLE 43 Europe Metabolic Disorders Market by Country, 2022 - 2028, USD Million
TABLE 44 Europe Hematologic Disorders Market by Country, 2018 - 2021, USD Million
TABLE 45 Europe Hematologic Disorders Market by Country, 2022 - 2028, USD Million
TABLE 46 Europe Neurological Conditions Market by Country, 2018 - 2021, USD Million
TABLE 47 Europe Neurological Conditions Market by Country, 2022 - 2028, USD Million
TABLE 48 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 49 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 50 Europe Rare Diseases Treatment Market by Country, 2018 - 2021, USD Million
TABLE 51 Europe Rare Diseases Treatment Market by Country, 2022 - 2028, USD Million
TABLE 52 Germany Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 53 Germany Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 54 Germany Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 55 Germany Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 56 Germany Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 57 Germany Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 58 Germany Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 59 Germany Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 60 Germany Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 61 Germany Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 62 UK Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 63 UK Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 64 UK Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 65 UK Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 66 UK Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 67 UK Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 68 UK Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 69 UK Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 70 UK Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 71 UK Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 72 France Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 73 France Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 74 France Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 75 France Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 76 France Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 77 France Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 78 France Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 79 France Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 80 France Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 81 France Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 82 Russia Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 83 Russia Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 84 Russia Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 85 Russia Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 86 Russia Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 87 Russia Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 88 Russia Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 89 Russia Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 90 Russia Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 91 Russia Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 92 Spain Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 93 Spain Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 94 Spain Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 95 Spain Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 96 Spain Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 97 Spain Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 98 Spain Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 99 Spain Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 100 Spain Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 101 Spain Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 102 Italy Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 103 Italy Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 104 Italy Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 105 Italy Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 106 Italy Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 107 Italy Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 108 Italy Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 109 Italy Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 110 Italy Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 111 Italy Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 112 Rest of Europe Rare Diseases Treatment Market, 2018 - 2021, USD Million
TABLE 113 Rest of Europe Rare Diseases Treatment Market, 2022 - 2028, USD Million
TABLE 114 Rest of Europe Rare Diseases Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 115 Rest of Europe Rare Diseases Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 116 Rest of Europe Rare Diseases Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 117 Rest of Europe Rare Diseases Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 118 Rest of Europe Rare Diseases Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 119 Rest of Europe Rare Diseases Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 120 Rest of Europe Rare Diseases Treatment Market by Therapeutic Area, 2018 - 2021, USD Million
TABLE 121 Rest of Europe Rare Diseases Treatment Market by Therapeutic Area, 2022 - 2028, USD Million
TABLE 122 Key information – AbbVie, Inc.
TABLE 123 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 124 Key Information – Bayer AG
TABLE 125 Key Information – Novartis AG
TABLE 126 key Information – Merck GrouP
TABLE 127 Key Information – Bristol Myers Squibb Company
TABLE 128 Key Information – Pfizer, Inc.
TABLE 129 KEY INFORMATION – ASTRAZENECA PLC
TABLE 130 Key Information – Takeda Pharmaceutical Company Limited
TABLE 131 Key Information – PTC Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
FIG 5 Recent strategies and developments: Pfizer, Inc.
FIG 6 Recent strategies and developments: PTC Therapeutics, Inc.